Amy Elazzouzi's most recent trade in Aura Biosciences Inc was a trade of 7,722 Common Stock done at an average price of $6.7 . Disclosure was reported to the exchange on Aug. 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Sale of securities on an exchange or to another person at price $ 6.70 per share. | 18 Aug 2025 | 7,722 | 86,558 | - | 6.7 | 51,737 | Common Stock |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.74 per share. | 18 Aug 2025 | 4,744 | 90,867 | - | 2.7 | 12,999 | Common Stock |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 4,744 | 0 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 2,554 | 0 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.07 per share. | 18 Aug 2025 | 2,554 | 83,935 | - | 5.1 | 12,949 | Common Stock |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 2,319 | 0 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.25 per share. | 18 Aug 2025 | 2,319 | 94,280 | - | 4.3 | 9,856 | Common Stock |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 1,094 | 0 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.16 per share. | 18 Aug 2025 | 1,094 | 91,961 | - | 3.2 | 3,457 | Common Stock |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.48 per share. | 18 Aug 2025 | 1,094 | 85,029 | - | 5.5 | 5,995 | Common Stock |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 1,094 | 0 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.21 per share. | 18 Aug 2025 | 547 | 86,123 | - | 5.2 | 2,850 | Common Stock |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.48 per share. | 18 Aug 2025 | 547 | 85,576 | - | 5.5 | 2,998 | Common Stock |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 547 | 0 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 547 | 0 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Sale of securities on an exchange or to another person at price $ 5.49 per share. | 16 Apr 2025 | 897 | 81,381 | - | 5.5 | 4,925 | Common Stock |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Sale of securities on an exchange or to another person at price $ 7.75 per share. | 18 Feb 2025 | 1,404 | 82,278 | - | 7.8 | 10,881 | Common Stock |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 45,240 | 83,682 | - | 0 | Common Stock | |
| Aura Biosciences Inc | Amy Elazzouzi | Senior Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 29,760 | 29,760 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Amy Elazzouzi | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 7.67 per share. | 21 Jan 2025 | 1,001 | 38,442 | - | 7.7 | 7,679 | Common Stock |
| Aura Biosciences Inc | Amy Elazzouzi | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 10.74 per share. | 29 Oct 2024 | 553 | 39,443 | - | 10.7 | 5,938 | Common Stock |